Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
TBC garadacimab Hereditary angioedema (HAE) Active
TBC delgocitinib Chronic hand eczema Pending
TBC rozanolixizumab Generalized myasthenia gravis (gMG) Active
TBC dabrafenib-trametinib Pediatric low grade glioma (ped LGG) Active
TBC pegcetacoplan Geographic atrophy secondary to age-related macular degeneration Active
TBC crovalimab paroxysmal nocturnal hemoglobinuria (PNH) Active
TBC teprotumumab Thyroid Eye Disease (TED), acute Received
TBC teprotumumab Thyroid Eye Disease (TED), chronic Received
TBD Cabozantinib Withdrawn
TBD Rituximab Cancelled